Alvogen ready to go with copy of world's top-selling cancer drug

12 February 2019

Privately-owned US drugmaker Alvogen has announced the launch of the first generic equivalent of Revlimid (lenalidomide) in a range of its operating central and eastern Europe (CEE) markets including Romania, Croatia, Bulgaria and the Baltic states.

Following the launch into CEE, the generic and bioequivivalent version of Revlimid will be launched globally in 2019, having been developed in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals.

"Having Lenalidomide in our portfolio also enhances our drive to be one of the key oncology players in the CEE region"Revlimid is indicated for the treatment of various oncology diseases including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. The reference product, from takeover target Celgene (Nasdaq: CELG), is the world’s biggest-selling cancer drug with approximately $9.8 billion sales globally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK